News
This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical Research Act.
(HealthDay News) — For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION), according ...
In this cohort study of individuals with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use was ...
Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 ...
Over time, these drugs have also been found to help people lose weight by slowing digestion, reducing hunger, and making ...
China’s drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...
7h
Fashion Glamp on MSNA Pivotal Advance in Obesity Treatment: Eli Lilly's Oral Pill Shows Significant Weight Loss in Landmark Trial
A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...
A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured.
Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results